Skip to content
AgingNexus
☰ Menu

Evidence brief · intervention

Rapamycin / mTOR inhibition

Synthesized from 10 indexed sources · 2026-07-27 MST · preview (no AI key)
Preview synthesis (deterministic, no AI key configured). Set a provider key to generate the full brief.

Synthesis (preview — no live AI key for the active provider):

Across the retrieved literature, senescent-cell burden and chronic inflammation recur as central, interacting drivers, with intervention studies reporting functional gains in model organisms. Key works: [1][2][3][4][5].

Set the active provider's API key to generate full model-written analysis.

Sources

  1. [1] Anti-Vascular Endothelial Growth Factors Protect Retinal Pigment Epithelium Cells Against Oxidation by Modulating Nitric Oxide Release and Autophagy
  2. [2] Upstream and downstream of mTOR
  3. [3] Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
  4. [4] PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
  5. [5] Targeting cancer stem cell pathways for cancer therapy
  6. [6] Mechanisms of Life Span Extension by Rapamycin in the Fruit Fly Drosophila melanogaster
  7. [7] The role of mitochondria in aging
  8. [8] Autophagy mediates the mitotic senescence transition
  9. [9] Bench to bedside: is rapamycin headed for the docTOR?
  10. [10] Autophagy reshapes the aging ER.
All Rapamycin / mTOR inhibition works → Intervention dossier →